title: Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.
abstract: S 16020, a new 9-OH olivacine derivative, is a novel topoisomerase II inhibitor with activity in cell lines presenting the classical multidrug resistance phenotype. This report summarizes, in addition to pharmacokinetic data, the whole phase I clinical experience of S 16020 using three different infusion schedules. Asthenia and skin toxicity were the main side effects. In an attempt to understand the skin toxicity mechanism, experiments in animals were performed, the results of which are reported. S 16020 showed rapid tumor necrotizing activity in some patients, with soft tissue metastases of epidermoïd tumors and pain at the tumor site. To document the side effects of S 16020 and tumor site reactions (pain, edema, inflammatory signs), inflammatory parameters and some cytokines were measured. In our patients there was no hemolysis and no detection of anti-S 16020 antibodies, confirming the absence of immunogenicity of the compound. Based on the overall data of the three infusion schedules of S 16020, the dose of 100 mg/m(2) over 3 h every 3 weeks was selected for phase II studies.
authors.affiliation: Jules Bordet Institute, Brussels, Belgium. ahmad.awada@bordet.be
authors.forename: A
authors.initials: A
authors.lastname: Awada
authors.forename: S
authors.initials: S
authors.lastname: Giacchetti
authors.forename: B
authors.initials: B
authors.lastname: Gerard
authors.forename: P
authors.initials: P
authors.lastname: Eftekhary
authors.forename: C
authors.initials: C
authors.lastname: Lucas
authors.forename: D
authors.initials: D
authors.lastname: De Valeriola
authors.forename: M G
authors.initials: MG
authors.lastname: Poullain
authors.forename: J
authors.initials: J
authors.lastname: Soudon
authors.forename: C
authors.initials: C
authors.lastname: Dosquet
authors.forename: M-H
authors.initials: MH
authors.lastname: Brillanceau
authors.forename: B
authors.initials: B
authors.lastname: Giroux
authors.forename: M
authors.initials: M
authors.lastname: Marty
authors.forename: H
authors.initials: H
authors.lastname: Bleiberg
authors.forename: F
authors.initials: F
authors.lastname: Calvo
authors.forename: M
authors.initials: M
authors.lastname: Piccart
mesh_terms: D000328:Adult; D000368:Aged; D001682:Biological Availability; D002227:Carbazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004611:Ellipticines; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D002227:Carbazoles; D004611:Ellipticines; C117470:NSC 659687; D011725:Pyridines; C011521:olivacine